PRQR
Price
$2.37
Change
-$0.08 (-3.27%)
Updated
Oct 6, 04:59 PM (EDT)
Capitalization
258.09M
30 days until earnings call
QNRX
Price
$7.42
Change
+$0.22 (+3.06%)
Updated
Oct 6, 04:32 PM (EDT)
Capitalization
4.23M
Interact to see
Advertisement

PRQR vs QNRX

Header iconPRQR vs QNRX Comparison
Open Charts PRQR vs QNRXBanner chart's image
ProQR Therapeutics
Price$2.37
Change-$0.08 (-3.27%)
Volume$6.73K
Capitalization258.09M
Quoin Pharmaceuticals
Price$7.42
Change+$0.22 (+3.06%)
Volume$200
Capitalization4.23M
PRQR vs QNRX Comparison Chart in %
PRQR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QNRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PRQR vs. QNRX commentary
Oct 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PRQR is a StrongBuy and QNRX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 06, 2025
Stock price -- (PRQR: $2.45 vs. QNRX: $7.20)
Brand notoriety: PRQR and QNRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PRQR: 76% vs. QNRX: 16%
Market capitalization -- PRQR: $258.09M vs. QNRX: $4.23M
PRQR [@Biotechnology] is valued at $258.09M. QNRX’s [@Biotechnology] market capitalization is $4.23M. The market cap for tickers in the [@Biotechnology] industry ranges from $103.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PRQR’s FA Score shows that 1 FA rating(s) are green whileQNRX’s FA Score has 1 green FA rating(s).

  • PRQR’s FA Score: 1 green, 4 red.
  • QNRX’s FA Score: 1 green, 4 red.
According to our system of comparison, both PRQR and QNRX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PRQR’s TA Score shows that 6 TA indicator(s) are bullish while QNRX’s TA Score has 3 bullish TA indicator(s).

  • PRQR’s TA Score: 6 bullish, 5 bearish.
  • QNRX’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, PRQR is a better buy in the short-term than QNRX.

Price Growth

PRQR (@Biotechnology) experienced а +16.11% price change this week, while QNRX (@Biotechnology) price change was -1.12% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.32%. For the same industry, the average monthly price growth was +14.86%, and the average quarterly price growth was +84.67%.

Reported Earning Dates

PRQR is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+7.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRQR($258M) has a higher market cap than QNRX($4.24M). PRQR YTD gains are higher at: -7.547 vs. QNRX (-68.386). QNRX has higher annual earnings (EBITDA): -12.58M vs. PRQR (-35.56M). PRQR has more cash in the bank: 120M vs. QNRX (7.79M). QNRX has less debt than PRQR: QNRX (6.21M) vs PRQR (16.9M). PRQR has higher revenues than QNRX: PRQR (16.5M) vs QNRX (0).
PRQRQNRXPRQR / QNRX
Capitalization258M4.24M6,092%
EBITDA-35.56M-12.58M283%
Gain YTD-7.547-68.38611%
P/E RatioN/A0.01-
Revenue16.5M0-
Total Cash120M7.79M1,540%
Total Debt16.9M6.21M272%
FUNDAMENTALS RATINGS
PRQR vs QNRX: Fundamental Ratings
PRQR
QNRX
OUTLOOK RATING
1..100
3198
VALUATION
overvalued / fair valued / undervalued
1..100
30
Undervalued
17
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
4187
P/E GROWTH RATING
1..100
10047
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

QNRX's Valuation (17) in the Biotechnology industry is in the same range as PRQR (30). This means that QNRX’s stock grew similarly to PRQR’s over the last 12 months.

QNRX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PRQR (100). This means that QNRX’s stock grew similarly to PRQR’s over the last 12 months.

PRQR's SMR Rating (98) in the Biotechnology industry is in the same range as QNRX (100). This means that PRQR’s stock grew similarly to QNRX’s over the last 12 months.

PRQR's Price Growth Rating (41) in the Biotechnology industry is somewhat better than the same rating for QNRX (87). This means that PRQR’s stock grew somewhat faster than QNRX’s over the last 12 months.

QNRX's P/E Growth Rating (47) in the Biotechnology industry is somewhat better than the same rating for PRQR (100). This means that QNRX’s stock grew somewhat faster than PRQR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PRQRQNRX
RSI
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
86%
Bullish Trend 4 days ago
90%
Momentum
ODDS (%)
Bullish Trend 4 days ago
84%
Bearish Trend 4 days ago
84%
MACD
ODDS (%)
Bullish Trend 4 days ago
85%
Bearish Trend 4 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
84%
Bearish Trend 4 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
83%
Bearish Trend 4 days ago
88%
Advances
ODDS (%)
Bullish Trend 4 days ago
85%
Bullish Trend 5 days ago
87%
Declines
ODDS (%)
Bearish Trend 12 days ago
84%
Bearish Trend 8 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
82%
Bearish Trend 4 days ago
83%
Aroon
ODDS (%)
Bearish Trend 4 days ago
81%
Bullish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
PRQR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QNRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EDNMY12.800.30
+2.40%
Edenred Malakoff
MARUF24.550.55
+2.30%
Marubeni Corp.
CZBS46.210.20
+0.43%
Citizens Bancshares Corp.
PMDKF0.05N/A
N/A
Pt Mitra Adiperkasa Tbk
DPXCF0.04N/A
-0.05%
DelphX Capital Markets Inc.